Literature DB >> 25085497

A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.

David Weill1, Christian Benden2, Paul A Corris3, John H Dark3, R Duane Davis4, Shaf Keshavjee5, David J Lederer6, Michael J Mulligan7, G Alexander Patterson8, Lianne G Singer5, Greg I Snell9, Geert M Verleden10, Martin R Zamora11, Allan R Glanville12.   

Abstract

The appropriate selection of lung transplant recipients is an important determinant of outcomes. This consensus document is an update of the recipient selection guidelines published in 2006. The Pulmonary Council of the International Society for Heart and Lung Transplantation (ISHLT) organized a Writing Committee of international experts to provide consensus opinion regarding the appropriate timing of referral and listing of candidates for lung transplantation. A comprehensive search of the medical literature was conducted with the assistance of a medical librarian. Writing Committee members were assigned specific topics to research and discuss. The Chairs of the Writing Committee were responsible for evaluating the completeness of the literature search, providing editorial support for the manuscript, and organizing group discussions regarding its content. The consensus document makes specific recommendations regarding the timing of referral and of listing for lung transplantation. These recommendations include discussions not present in previous ISHLT guidelines, including lung allocation scores, bridging to transplant with mechanical circulatory and ventilator support, and expanded indications for lung transplantation. In the absence of high-grade evidence to support decision making, these consensus guidelines remain part of a continuum of expert opinion based on available studies and personal experience. Some positions are immutable. Although transplant is rightly a treatment of last resort for end-stage lung disease, early referral allows proper evaluation and thorough patient education. Subsequent waiting list activation implies a tacit agreement that transplant offers a significant individual survival advantage. It is both the challenge and the responsibility of the transplant community globally to ensure organ allocation maximizes the potential benefits of a scarce resource, thereby achieving that advantage.
Copyright © 2015 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cystic fibrosis; emphysema; interstitial lung disease; lung transplantation; pulmonary hypertension

Mesh:

Year:  2014        PMID: 25085497     DOI: 10.1016/j.healun.2014.06.014

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  257 in total

1.  ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine.

Authors:  Gaëtane C Michaud; Colleen L Channick; Chad R Marion; Robert M Tighe; James A Town; Andrew M Luks; Jeremy B Richards; Sucharita Kher; Prerna Mota; Gina Hong; Natalie E West; Craig Rackley; Luke Neilans; Josanna Rodriguez-Lopez; Hilary DuBrock; Cassie C Kennedy; Diana J Kelm; Carey C Thomson
Journal:  Ann Am Thorac Soc       Date:  2015-09

2.  ATS Core Curriculum 2015: Part III. Pediatric Pulmonary Medicine.

Authors:  Debra Boyer; Mary Nevin; Carey C Thomson; Don B Sanders; Stamatia Alexiou; Samuel B Goldfarb; Jennifer L Nicholas; Paul G Thacker; Andrea M Coverstone; Albert Faro; George Cheng; Adnan Majid; Paul E Moore
Journal:  Ann Am Thorac Soc       Date:  2015-11

3.  Machine Learning and Prediction of All-Cause Mortality in COPD.

Authors:  Matthew Moll; Dandi Qiao; Elizabeth A Regan; Gary M Hunninghake; Barry J Make; Ruth Tal-Singer; Michael J McGeachie; Peter J Castaldi; Raul San Jose Estepar; George R Washko; James M Wells; David LaFon; Matthew Strand; Russell P Bowler; MeiLan K Han; Jorgen Vestbo; Bartolome Celli; Peter Calverley; James Crapo; Edwin K Silverman; Brian D Hobbs; Michael H Cho
Journal:  Chest       Date:  2020-04-27       Impact factor: 9.410

Review 4.  Heart-lung transplantation: current indications, prognosis and specific considerations.

Authors:  Jérôme Le Pavec; Sébastien Hascoët; Elie Fadel
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

5.  How important is social support in determining patients' suitability for transplantation? Results from a National Survey of Transplant Clinicians.

Authors:  Keren Ladin; Joanna Emerson; Zeeshan Butt; Elisa J Gordon; Douglas W Hanto; Jennifer Perloff; Norman Daniels; Tara A Lavelle
Journal:  J Med Ethics       Date:  2018-06-28       Impact factor: 2.903

Review 6.  Non-tuberculous Mycobacterial Infections in Thoracic Transplant Candidates and Recipients.

Authors:  Mana Rao; Fernanda P Silveira
Journal:  Curr Infect Dis Rep       Date:  2018-05-12       Impact factor: 3.725

7.  Improvement in patient-reported outcomes after lung transplantation is not impacted by the use of extracorporeal membrane oxygenation as a bridge to transplantation.

Authors:  Nicholas A Kolaitis; Allison Soong; Pavan Shrestha; Hanjing Zhuo; John Neuhaus; Patti P Katz; John R Greenland; Jeffrey Golden; Lorriana E Leard; Rupal J Shah; Steven R Hays; Jasleen Kukreja; Mary Ellen Kleinhenz; Paul D Blanc; Jonathan P Singer
Journal:  J Thorac Cardiovasc Surg       Date:  2018-02-22       Impact factor: 5.209

Review 8.  Lung volume reduction followed by lung transplantation-considerations on selection criteria and outcome.

Authors:  Alexis Slama; Christian Taube; Markus Kamler; Clemens Aigner
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 9.  Transplant options for end stage chronic obstructive pulmonary disease in the context of multidisciplinary treatments.

Authors:  Luigi Santambrogio; Paolo Tarsia; Paolo Mendogni; Davide Tosi
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 10.  Lung cancer: a rare indication for, but frequent complication after lung transplantation.

Authors:  Dirk Van Raemdonck; Robin Vos; Jonas Yserbyt; Herbert Decaluwe; Paul De Leyn; Geert M Verleden
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.